RxDoctor Payments Data

Raymond Otto, MD

Undersea and Hyperbaric Medicine · Boise, IDNPI 1063455301

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Acera Surgical, Inc. at 31.5% of the total. Reporting peaked in 2019 at $332 and has fallen 89.8% since, to $34 in 2025.

$1,130in general payments, 2019–2025

Across 18 payments — averaging $62.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acera Surgical, Inc.$356
  • KCI USA, Inc.$139
  • Medtronic$109
  • Organogenesis Inc.$105
  • Innovation Technologies Inc$88
  • Osiris Therapeutics Inc.$85
  • plus $247 from 7 others
$3,150in research payments, 2019–2025

Across 4 payments — averaging $787.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Organogenesis Inc.$3K

What the payments were for

  • Food & beverage$1,130100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few undersea and hyperbaric medicine providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$91,420
Medicare patients
320
Services billed
1,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate76$1,026
Mupirocin88$768
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav42$614
Triamcinolone Acetonide58$251
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$236
Cefadroxil20$216
Nystatin20$173
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$149
Ciprofloxacin Hcl16$144
Fluconazole11$144
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$90
Levofloxacin15$71

Paid to pharmacies, not to this prescriber.

Other undersea and hyperbaric medicine in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →